A two-drug melanoma treatment had an estimated 70% survival at two years in 17 patients.
Immunocore (IMCR) presented Phase 1/2 trial data at SITC 2026, showing a 70% estimated two-year survival rate in 17 patients treated with brenetafusp and KIMMTRAK for metastatic uveal melanoma. The combination demonstrated clinical activity and a manageable safety profile. The company plans a Phase 2/3 trial (DUET-UVEAL) to further evaluate the treatment.
How this was made
The 30-second read
Why it matters
The presented data could catalyze a re‑rating of IMCR and similar companies pursuing T‑cell engager platforms.
Market read
First‑time survival data for a novel combination therapy, likely to move IMCR and influence biotech sector sentiment.
What to watch
Small patient cohort (17) and lack of control arm limit robustness of the results.
Background
Immunocore is a commercial‑stage biotech developing ImmTAC bispecific T‑cell receptor therapies.
Ticker impact
Immunocore (Nasdaq: IMCR) presented Phase 1/2 data showing ~70% two‑year overall survival in 17 uveal melanoma patients, the first such data for the brenetafusp + KIMMTRAK combo.
upward pressure as market prices in the encouraging survival data
Phase 1 data with strong survival signals are rare and can drive near‑term price gains for biotech stocks.
Market effects
May increase interest in T‑cell engager therapies and boost related biotech peers.
Limited to US and European biotech markets where Immunocore is listed.
Highlights progress in immunotherapy for rare cancers, relevant to global oncology investors.
Counterpoint
Early‑stage data can be misleading; later trials may not confirm survival benefit.
Key entities
- companyImmunocore Holdings plc
Developer of ImmTAC therapies, listed on Nasdaq as IMCR.
- drugKIMMTRAK
Approved bispecific T‑cell receptor therapy for uveal melanoma.
- drugbrenetafusp
Investigational ImmTAC targeting PRAME antigen.
